Hepatitis C Management in Special Populations
Summary
- Data show that HCV therapy with DAAs is highly effective and safe in persons with active or recent IDU and/or who are receiving OST, with SVR12 rates exceeding 90% in these populations[Feld 2014; Grebely 2017; Grebely 2016a; Grebely 2016b; Zeuzem 2015; Dore 2016; Foster 2017]
- Guidelines from both the AASLD and EASL recommend HCV treatment of PWID in conjunction with linkage to harm-reduction strategies[AASLD-IDSA HCV; EASL HCV]
- Some cases of HCV reinfection should be expected among PWID following HCV clearance due to ongoing risk behavior[Simmons 2016]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C, Hepatitis C-Special Populations